The Ottawa-based molecular diagnostics maker also plans to enter applied markets in the near term, and ultimately point-of-care infectious disease testing.
The agency plans to make test kits available to state and international partners in the next two weeks. It also provided updated information about the virus.
The startup is exploring options with potential partners and plans to bring a urinary tract infection test through regulatory channels in the next two years.
A study of the firm's tests to detect bacterial vaginosis, yeast infections, and trichomoniasis, show they can potentially improve treatment for women with vaginitis.
Microbiology lab and industry stakeholders are increasingly working together to coordinate approaches and generate more clinical utility data for diagnostic testing.
The method, dubbed GoPhAST-R, was codeveloped by researcher from the Broad Institute and NanoString, which now hopes to work with a partner to commercialize it.
The firm's tick-borne pathogens panel was also recently the subject of a clinical study, showing high accuracy in detecting numerous infectious agents.
In Cell this week: proteomic, genomic, and transcriptomic analysis of endometrial cancer; deep neural network learning-based approach to antibiotic discovery; and more.
